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Abstract 
All cancers depend upon mutations in critical genes, which confer a selective 
advantage to the tumour cell. Knowledge of these mutations is crucial to 
understanding the biology of cancer initiation and progression, and to the 
development of targeted therapeutic strategies.  The key to understanding the 
contribution of a disease-associated mutation to the development and 
progression of cancer, comes from an understanding of the consequences of 
that mutation on the function of the affected protein, and the impact on the 
pathways in which that protein is involved.  
In this paper we examine the mutation patterns observed in oncogenes and 
tumour suppressors, and discuss different approaches that have been 
developed to identify driver mutations within cancers that contribute to the 
disease progress.  We also discuss the MOKCa database where we have 
developed an automatic pipeline that structurally and functionally annotates all 
proteins from the human proteome that are mutated in cancer. 
 
Introduction 
In most diseases of genetic origin, the disease phenotype can usually be 
attributed to a small number of defined mutations, which once located are 
readily distinguished from the essentially wild-type genetic background [1]. 
Cancer is also fundamentally a genetic disease, with the phenotype arising by 
somatic acquisition of a set of defined ‘hallmark’ mutations [2]. These exert 
their effect by activating oncogenes and/or inactivating tumour suppressors, 
one or more of which may already be mutated in the germline in inherited 
cancer predispositions syndromes. 
 3
Acquisition of the genetic changes that confer hallmark traits of invasive 
cancer depends on loss of genetic stability early in the tumour cell lineage 
typically initiated by a defect in the DNA damage response (DDR) [3]. 
Paradoxically, the inherent genetic instability that gives tumours their 
evolutionary plasticity underlies their sensitivity to the genotoxic drugs and 
radiation that constitute many first-line cancer therapies. An important 
consequence of this genetic instability is the presence of large numbers of 
mutational changes in the genomes of tumours as compared to 
untransformed cells from the same individual [4]. The overwhelming majority 
of these changes may be inconsequential in terms of driving the cancer 
phenotype, but generate a high level of mutational ‘noise’ within which the 
significant driving mutations may be very difficult to identify. 
There has been a substantial increase in understanding of the many 
pathways that can drive the hallmark traits of cancer in the last few years[5], 
and many specific inhibitors of the proteins that constitute those pathways 
have been developed. Together with the development of rapid and low-cost 
genome sequencing, there is now the real prospect of ‘personalised’ drug 
therapies precisely targeted to the idiosyncratic regulatory malfunctions 
resulting from the mutations that drive an individual cancer [6], so long as 
these can be distinguished from the substantial background of irrelevant 
‘passenger’ mutations, so that the genotype can be used to predict the 
phenotype . 
Given the large numbers of mutations typically observed [7] experimental 
determinations of the consequences on protein function of the individual 
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mutations observed in a cancer genome are not realistic, and computational 
approaches are required.  
 
Identifying Driver Genes  
These are several statistical approaches (eg [8, 9]) that identify significantly 
mutated genes within large cohorts of sequenced tumours.  These 
approaches are very good at identifying highly recurrent mutated genes but as 
yet, the data sets are not large enough to have the statistical power to detect 
low frequency mutated genes that contribute to the initiation and progression 
of cancer.  This can pose a problem because although a few genes are highly 
mutated, the majority of somatic mutations occur in genes that are 
infrequently mutated [10, 11]. 
 
Characteristics of Tumour Suppressors and Oncogenes 
Driver genes are classified by the manner in which, when mutated, they 
contribute to the disease process. Tumour suppressors contribute to the 
development of cancer when mutations (or in some instances epigenetic 
silencing) result in their loss of function (LOF).  The alterations to these genes 
are generally molecularly recessive where both copies of the gene require a 
LOF defect to cause disease [12].   For instance, this may be a truncation or 
missense mutation on one allele, combined with a complete loss of the 
second.  This commonly occurs in kidney renal clear cell carcinoma (KIRC), 
where the loss of the chromosome arm 3p in KIRC combined with concurrent 
mutations on the remaining allele results in complete ablation of functioning 
VHL [13].   
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In oncogenes, an increase in activity, or a change of function is required for 
tumorigenesis. They tend to exhibit a molecularly dominant mode of action, 
and usually only one defective copy of the gene is required to provide an 
oncogenic phenotype.  This is exhibited in BRAF where V600E activating 
mutations constitutively activates BRAF in malignant melanoma [14], or in 
BCR-ABL in chronic myelogenous leukaemia where a translocation 
constitutively activates ABL-kinase.   
 
Missense mutations in tumour suppressors can result in its loss of function in 
a variety of manners including loss of stability of the protein or the disruption 
of a crucial ligand/DNA/protein-binding site [15]. In cohorts of tumours, these 
mutations are often liberally dispersed along the length of the gene, as protein 
function can be disrupted by mutations at a multitude of positions [16]. 
Conversely, in oncogenes, driver missense mutations tend to cluster at 
distinct locations in the amino acid sequence impacting on sites of protein-
protein interaction, allosteric regulation, post-translational modification or 
ligand-binding. Often only a very few, specific mutations can lead to activation 
of the protein product or a change of a protein function [16].  
 
Identifying driver mutations 
Sequence and structural data have been utilised to predict whether a 
missense mutation or a small insertion or deletion could be disease-causing 
using a variety of approaches.  Sequence conservation is used to predict 
which mutations can be tolerated within a protein structure, and similarly, 
protein structures have been used for estimating how disruptive a missense 
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mutation may be [15, 17-20].  Techniques originally developed to predict the 
consequences of amino-acid changes observed in SNPs and Mendelian 
genetic diseases, have been applied to cancer mutations, but have often 
failed to provide sufficiently reliable prediction.  
More recently algorithms have been specifically developed to distinguish 
cancer-associated somatic driver mutations from passenger mutations. These 
include profile-based methods for assessing missense mutations (eg [21-24]), 
and machine learning algorithms for assessing the pathogenicity of missense 
mutations [25] and indels [26]. 
 
Approaches to distinguish between tumour suppressors and oncogenes 
As the mutational patterns observed in cohorts of tumour samples clearly 
differ between tumour suppressor and oncogenes, several groups have used 
this information to automatically distinguish between them.  For instance, 
Vogelstein’s 20:20 rule [16] states that if 20% of all mutations observed in a 
gene within a cohort of tumour samples are truncations, then that gene is 
likely to be a tumour suppressor, where as if 20% of all missense mutations 
occur at a single position in the sequence, the gene is predicted to be an 
oncogene.  These types of patterns have also been included in machine 
learning algorithms to automatically distinguish between tumour suppressors 
and oncogenes (eg [27]) using data from whole exome sequencing. 
 
 
MOKCa database 
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The MOKCa database [28] (http://strubiol.icr.ac.uk/extra/mokca/) was 
developed to structurally and functionally annotate, and where possible 
predict, the phenotypic consequences of disease-associated mutations in 
protein kinases implicated in cancer. We have recently extended the database 
to include all the proteins from the human genome that are mutated in cancer 
(see supplementary figure 1).  
Somatic mutation data from the COSMIC database [7] have been mapped to 
their position in UniProt sequences [29].  Each mutation is described by its 
alteration to the protein structure, eg V600E.  When a mutation has been 
reported on more one occasion, it is stored as an “aggregate” mutation and 
the number of observations of the aggregate mutation is recorded.  Different 
genetic changes that result in the same protein coding mutation are presented 
together at the protein level and each disease type in which this mutation has 
been recorded is also presented on the protein overview page. 
Functional annotations for each protein are displayed.  These include the 
identification and position of Pfam domain assignments within the protein 
sequence [30], and the positions of residues effected by post-translational 
modifications including phosphorylation, glycosylation, and ubiquitination [31]. 
Gene Ontology (GO) annotations have also been obtained for each protein 
[32]. 
 
Structural Mapping of Mutations 
The amino acid sequence for every Pfam-annotated domain for which 
COSMIC records a cancer-associated mutation has been scanned against the 
Protein Data Bank (PDB) [33] using BLAST/PSI-BLAST [34], to map the 
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mutation onto the protein structure of the affected human protein domains 
where the structure has been experimentally determined, or onto the most 
closely related homologous structure where the experimental structure is not 
known. 
The positions of the individual mutations can be viewed on the mutation web 
page using the Jmol application [35], and the multiple sequence alignment 
between the query domain and the PDB template is displayed using Jalview 
[36]. 
 
Development of web-interface 
The new web-interface for MOKCa database can accessed at 
http://strubiol.icr.ac.uk/extra/mokca/ (see figure 1) and can be searched by 
gene name or by UniProt accession [29].  
Users can also browse the data using gene names either exploring the 
complete genome or our curated sets of genes that are implicated in cancer.   
These include, protein kinases, oncogenes and tumour suppressors, proteins 
involved in the DNA damage response (DDR) [37] and those proteins that are 
current targets of chemotherapy and personalised cancer medicine regimes 
(drug targets) [38].   
 
Activating mutations in oncogenes 
Analysis of data in the MOKCa database suggests that although there are a 
large number of ways to inactivate the protein product of a gene, there are 
probably only a limited number of ways that small mutations (missense, 
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truncations, indels) are able to activate them. We have identified several 
common mechanisms of activation - some of these are highlighted below. 
 
Activating mutations in protein kinases  
Protein kinases can be thought of being in equilibrium between the open and 
closed conformations.  Usually, other protein kinases phosphorylate the 
activating residues (S/T/Y) -moving the conformational equilibrium towards 
the open, active conformation (See Figure 2), whereas protein phosphatases 
remove the phosphate groups shifting the conformational equilibrium back to 
the closed, inactive conformation.  These processes leads to highly regulated 
control of the conformation and activation of kinase domains.   
One of the most frequently reported mutations is the activating mutation 
V600E in B-Raf, a driver missense mutation in malignant melanoma.  
Examination of V600E mutation models using the SAAPdat tool [15] (Figure 
3), clearly shows that the structural impact of the mutation differs in the active 
and inactive conformations of the protein.  The mutation is predicted to be 
structurally tolerated when the BRAF kinase domain is in the open, active 
conformation, yet in the closed, inactive conformation the mutation is 
predicted to introduce a hydrophilic residue and a buried charge into the core 
of the protein.  This would result in the destabilisation of the inactive 
conformation, moving the equilibrium of the protein towards the active 
conformation where the mutation is better tolerated.   
Recent molecular dynamic simulations support this model, suggesting that the 
V600E mutation increases the energy barrier of the transition from the active 
to inactive conformation, trapping B-Raf in the active state.  They also suggest 
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that an increase in the flexibility of the activation loop may also speed-up 
phosphorylation [39].  
Dependant on their location within the kinase domain, missense mutations will 
often be better tolerated in one or other conformation of the protein kinase 
resulting in an alteration of the conformational equilibrium and constitutive 
activation (or in some cases deactivation) of the protein kinase.   
Another observed mechanism for the constitutive activation of protein kinases 
is the loss of inhibitory phosphorylation sites.  These include the auto 
inhibitory phosphorylation sites in KIT at position Y823 (D/C/N mutations) and 
the S259A mutation in the PKC phosphorylation site in Raf1, that mediates 
inhibitory 14-3-3 protein [40].  Tyrosine receptor kinases can also be activated 
by dimerization of the extracellular domains resulting in ligand-independent 
activation of the receptor.  This is observed in FGFR2  by mutations R203C 
and W290C in the immunoglobulin-like  (Ig-like) domains [41, 42]. 
 
 
Oncogenic mutations in isocitrate dehydrogenases  
Mutations in isocitrate dehydogenases are also thought to contribute to the 
progression of cancer by altering the conformation of the protein.  IDH1 and 
IDH2 catalyse the oxidative carboxylation of isocitrate to α-ketoglutarate.  
Mutational hotspots at R132H in IDH1, and R140Q and R172K in IDH2 alter 
the progression of this reaction.  Recent structural work suggests that the 
R132H IDH1 mutation hampers the conformational change from the initial 
isocitrate binding state to the pre-transition state, thus causing an impairment 
of enzyme function [43].  This alters the progression of this reaction causing 
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the oncometabolite R(-)-2-hydroxyglutarate to be formed. R(-)-2-
hydroxyglutarate is implicated in genomic hypermethylation, leading to histone 
methylation, genomic instability, and finally malignant transformation  [44]. 
 
Domain-based approaches at identifying mutational hotspots 
Although most of the analysis of cancer mutations is based around a gene 
centric view, a few studies have focused on domain-based analyses [45, 
46][50] and they may be particularly fruitful when studying mechanisms of 
activation of proteins. Larger proteins comprise recognizable smaller 
sequence domains, which recur in other proteins in various combinations. 
These domains may be thought of as units of evolution, creating protein 
domain families, and have evolved from a common ancestor. As a domain 
can exist across multiple proteins with conserved function and structure, it 
follows that similarly located mutations across different proteins in the same 
domain should have similar effects on the function of that domain.   
Proteome-wide analyses have been performed to identify domains enriched in 
missense mutations [45, 47]  [50] and to identify domain-centric positions of 
hotspot missense mutations [48, 49] [50].  These studies focused exclusively 
on missense mutation and as yet, little attempt was to use these data to 
distinguish between activating and loss of function mutations in the majority of 
cases.  
We are currently mapping all simple small mutations (missense, truncations 
and indels) from over thirty different types of cancer to equivalent positions in 
multiple sequence alignments of protein domains.  These data are being used 
to identify domain-centric mutational hotspots and can be accessed through 
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the MOKCa database.   
Using the biological knowledge associated with protein domains, such as 
structural information and evolutionary conservation, will enable us to 
understand the functional consequences of infrequent mutations in well-
characterised domain families and will facilitate additional insights into the 
roles of these mutations in cancer.  
 
Figure Legends  
Figure 1: This is an illustration of the data visualisation available on the 
different webpages on MOKCa web-interface.  Figure (a) shows sets of 
cancer-related genes that can be browsed by gene name.  Figure (b) shows a 
schematic diagram of the domain architecture of the protein (BRAF) with the 
positions of somatic mutations mapped to the protein sequence.  Blue lines 
indicate missense mutations, dotted black lines indicate silent mutations and 
triangles are used to show insertions (pointing down) or deletions (pointing 
up).  In frame indels are coloured blue, and frame shift indels are coloured 
green, solid black lines indicate nonsense mutations.  Figure (c) is an extract 
from the summary table for mutation aggregates.  As well as describing the 
mutations and their frequency it also indicates which domain the mutation is 
in, whether it is near any post-translational modifications and highlights which 
cancers it is found in. Figure (d) shows in more detail the post-translational 
modifications near the mutation.  Figure (e) highlights the position of the 
mutation within a protein structure. In the example shown, the domain 
containing the mutation, a protein kinase domain (Pkinase), is coloured in red, 
 13
and the mutated residue is displayed as a space filling model. Figure (f) 
displays the distinct number of protein coding mutations (aggregates) found in 
each gene. 
 
Figure 2:  This is a schematic illustration of the change in the equilibrium of 
the active/open and inactive/closed conformational states of protein kinases.  
Figure (a) shows the default equilibrium of a protein kinase. When the 
activation loop is phosphorylated, the active conformer is stabilised and the 
equilibrium moves toward the active conformation.  This is illustrated in figure 
(b).  Activating mutations have a tendency to destabilise the inactive 
conformation also moving the equilibrium towards the active conformation.  
This is illustrated in figure (c). 
 
Figure 3:  Figures (a) and  (b) show the structural impact of the V600E 
mutation in the protein product of BRAF as predicted by the SAAP [15] 
algorithm.  The predicted impact of the mutation differs significantly 
dependent on whether the protein is in the (a) active or (b) inactive protein 
kinase conformation.  Figures (c) and (d) show the predicted positions of the 
V600E mutation within the protein structure.  The position of the mutated 
residue also differs significantly depending on whether the protein is in the (c) 
active or (d) inactive protein kinase conformation.  Figure (c) is modelled on 
the PDB template 3PSD, chain B, and figure (d) on 3SKC chain B. 
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Supplementary Figure 1 
 
This figure outlines the steps required to populate the MoKCA database. 
Mutation mapping:  All Cosmic mutations are analysed at the protein level and 
clustered into aggregate mutations.  The positions of these mutations are then 
re-mapped onto the UniProt protein sequence using a Cosmic to UniProt 
pairwise protein sequence alignment. 
Sequence Alignments:  Protein sequences downloaded from the Cosmic 
database are scanned against all human UniProt sequences.  A pairwise 
sequence alignment is obtained for each Cosmic sequence to the nearest 
UniProt sequence found.   
Pfam domain assignments:  Domain boundaries for UniProt sequences are 
extracted from the Pfam database and domain sequence files constructed.  
Each domain sequence is then scanned against the PDB sequence library 
and the best ten matches are then realigned using a dynamic programming 
algorithm.  These domain sequence alignments are used to map both the 
Pfam and mutational data onto the PDB structures for visualisation on the 
web-pages. 
Posttranslational modifications are directly mapped onto UniProt protein 
sequences.  Other functional annotation is extracted from external databases 
using the UniProt accession code.  
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